TY - JOUR
T1 - Outside-binding site mutations modify the active site's shapes in neuraminidase from influenza A H1N1
AU - Tolentino-Lopez, Luis
AU - Segura-Cabrera, Aldo
AU - Reyes-Loyola, Paola
AU - Zimic, Mirko
AU - Quiliano, Miguel
AU - Briz, Veronica
AU - Muñoz-Fernández, Angeles
AU - Rodríguez-Pérez, Mario
AU - Ilizaliturri-Flores, Ian
AU - Correa-Basurto, Jose
PY - 2013/1
Y1 - 2013/1
N2 - The recent occurrence of 2009 influenza A (H1N1) pandemic as well as others has raised concern of a far more dangerous outcome should this virus becomes resistant to current drug therapies. The number of clinical cases that are resistant to oseltamivir (Tamiflu®) is larger than the limited number of neuraminidase (NA) mutations (H275Y, N295S, and I223R) that have been identified at the active site and that are associated to oseltamivir resistance. In this study, we have performed a comparative analysis between a set of NAs that have the most representative mutations located outside the active site. The recently crystallized NA-oseltamivir complex (PDB ID: 3NSS) was used as a wild-type structure. After selecting the target NA sequences, their three-dimensional (3D) structure was built using 3NSS as a template by homology modeling. The 3D NA models were refined by molecular dynamics (MD) simulations. The refined models were used to perform a docking study, using oseltamivir as a ligand. Furthermore, the docking results were refined by free-energy analysis using the MM-PBSA method. The analysis of the MD simulation results showed that the NA models reached convergence during the first 10 ns. Visual inspection and structural measures showed that the mutated NA active sites show structural variations. The docking and MM-PBSA results from the complexes showed different binding modes and free energy values. These results suggest that distant mutations located outside the active site of NA affect its structure and could be considered to be a new source of resistance to oseltamivir, which agrees with reports in the clinical literature. © 2012 Wiley Periodicals, Inc.
AB - The recent occurrence of 2009 influenza A (H1N1) pandemic as well as others has raised concern of a far more dangerous outcome should this virus becomes resistant to current drug therapies. The number of clinical cases that are resistant to oseltamivir (Tamiflu®) is larger than the limited number of neuraminidase (NA) mutations (H275Y, N295S, and I223R) that have been identified at the active site and that are associated to oseltamivir resistance. In this study, we have performed a comparative analysis between a set of NAs that have the most representative mutations located outside the active site. The recently crystallized NA-oseltamivir complex (PDB ID: 3NSS) was used as a wild-type structure. After selecting the target NA sequences, their three-dimensional (3D) structure was built using 3NSS as a template by homology modeling. The 3D NA models were refined by molecular dynamics (MD) simulations. The refined models were used to perform a docking study, using oseltamivir as a ligand. Furthermore, the docking results were refined by free-energy analysis using the MM-PBSA method. The analysis of the MD simulation results showed that the NA models reached convergence during the first 10 ns. Visual inspection and structural measures showed that the mutated NA active sites show structural variations. The docking and MM-PBSA results from the complexes showed different binding modes and free energy values. These results suggest that distant mutations located outside the active site of NA affect its structure and could be considered to be a new source of resistance to oseltamivir, which agrees with reports in the clinical literature. © 2012 Wiley Periodicals, Inc.
KW - docking
KW - molecular dynamics
KW - neuraminidase
UR - http://www.scopus.com/inward/record.url?scp=84867841322&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867841322&partnerID=8YFLogxK
U2 - 10.1002/bip.22130
DO - 10.1002/bip.22130
M3 - Article
C2 - 23097226
AN - SCOPUS:84867841322
SN - 0006-3525
VL - 99
SP - 10
EP - 21
JO - Biopolymers
JF - Biopolymers
IS - 1
ER -